Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update

Arvinas, Inc. (NASDAQ:ARVN) was the recipient of a large decline in short interest during the month of January. As of January 30th, there was short interest totaling 4,262,275 shares, a decline of 15.6% from the January 15th total of 5,052,067 shares. Based on an average daily volume of 720,790 shares, the short-interest ratio is currently 5.9 days. Approximately 7.0% of the company’s shares are short sold. Approximately 7.0% of the company’s shares are short sold. Based on an average daily volume of 720,790 shares, the short-interest ratio is currently 5.9 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. TCG Crossover Management LLC acquired a new position in Arvinas during the third quarter valued at approximately $13,780,000. Acadian Asset Management LLC boosted its position in shares of Arvinas by 791.1% during the second quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock worth $10,498,000 after purchasing an additional 1,267,593 shares in the last quarter. Balyasny Asset Management L.P. grew its holdings in shares of Arvinas by 469.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company’s stock valued at $10,286,000 after buying an additional 995,125 shares during the period. Qube Research & Technologies Ltd increased its position in shares of Arvinas by 154.8% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock valued at $12,668,000 after buying an additional 903,337 shares in the last quarter. Finally, Millennium Management LLC increased its position in shares of Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock valued at $9,198,000 after buying an additional 885,483 shares in the last quarter. Institutional investors own 95.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ARVN shares. Stephens increased their price objective on Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, November 10th. Barclays raised their price target on Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Wedbush reiterated a “neutral” rating and issued a $9.00 price objective on shares of Arvinas in a research report on Thursday, November 6th. BTIG Research boosted their price objective on Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. Ten equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.12.

Arvinas Trading Down 1.6%

NASDAQ ARVN opened at $11.65 on Monday. Arvinas has a 12 month low of $5.90 and a 12 month high of $20.38. The stock has a 50-day simple moving average of $12.47 and a 200 day simple moving average of $10.26. The company has a market capitalization of $748.16 million, a PE ratio of -14.38 and a beta of 1.88.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.